OBJECTIVE: Various nonestrogenic therapies have been found to be effective in mitigating hot flashes, but it has been unclear whether the efficacy varies by whether women have had breast cancer and/or were takingtamoxifen. METHODS: This study used data from Mayo Clinic/North Central Cancer Treatment Group clinical trials that evaluated the efficacy of any nonestrogenic agent for hot flashes and had information on breast cancer history or tamoxifen use. Statistically significant changes from the fourth treatment week versus the baseline week, using individual patient data, were assessed using Student's t test. RESULTS: A total of 1,396 women from 20 hot flash studies were eligible for analysis. Overall, women without breast cancer had a similar percentage of baseline hot flash score at week 4, as did those with breast cancer (53% vs 50%, P = 0.92). Women who were not taking tamoxifen had a significantly lower percentage of hot flash score at week 4 as compared with those who used tamoxifen (54% vs 61%, P = 0.01). However, this was due to a higher reduction in hot flash scores in the placebo arms among women not receiving tamoxifen; the percentage reduction in hot flash scores at week 4 from baseline in the active therapy arms of the randomized placebo-controlled trials (ie, excluding placebo arms) was similar among the tamoxifen users and nonusers (difference in mean percentage reduction, 5.7; 95% CI, -1.76 to 13.16). CONCLUSIONS: Some nonestrogenic therapies seem to be useful for reducing hot flashes, irrespective of the etiology of hot flashes.
RCT Entities:
OBJECTIVE: Various nonestrogenic therapies have been found to be effective in mitigating hot flashes, but it has been unclear whether the efficacy varies by whether women have had breast cancer and/or were taking tamoxifen. METHODS: This study used data from Mayo Clinic/North Central Cancer Treatment Group clinical trials that evaluated the efficacy of any nonestrogenic agent for hot flashes and had information on breast cancer history or tamoxifen use. Statistically significant changes from the fourth treatment week versus the baseline week, using individual patient data, were assessed using Student's t test. RESULTS: A total of 1,396 women from 20 hot flash studies were eligible for analysis. Overall, women without breast cancer had a similar percentage of baseline hot flash score at week 4, as did those with breast cancer (53% vs 50%, P = 0.92). Women who were not taking tamoxifen had a significantly lower percentage of hot flash score at week 4 as compared with those who used tamoxifen (54% vs 61%, P = 0.01). However, this was due to a higher reduction in hot flash scores in the placebo arms among women not receiving tamoxifen; the percentage reduction in hot flash scores at week 4 from baseline in the active therapy arms of the randomized placebo-controlled trials (ie, excluding placebo arms) was similar among the tamoxifen users and nonusers (difference in mean percentage reduction, 5.7; 95% CI, -1.76 to 13.16). CONCLUSIONS: Some nonestrogenic therapies seem to be useful for reducing hot flashes, irrespective of the etiology of hot flashes.
Authors: Barbara A Pockaj; James G Gallagher; Charles L Loprinzi; Philip J Stella; Debra L Barton; Jeff A Sloan; Beth I Lavasseur; Radha M Rao; Tom R Fitch; Kendrith M Rowland; Paul J Novotny; Patrick J Flynn; Elliott Richelson; Abdul H Fauq Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Michele L Evans; Elizabeth Pritts; Eric Vittinghoff; Karen McClish; Kevin S Morgan; Robert B Jaffe Journal: Obstet Gynecol Date: 2005-01 Impact factor: 7.661
Authors: Domingo G Perez; Charles L Loprinzi; Debra L Barton; Barbara A Pockaj; Jeff Sloan; Paul J Novotny; Bradley J Christensen Journal: J Support Oncol Date: 2004 Jan-Feb
Authors: Susan Thompson; Aditya Bardia; Angelina Tan; Debra L Barton; Lisa Kottschade; Jeff A Sloan; Brad Christensen; DeAnne Smith; Charles L Loprinzi Journal: Support Care Cancer Date: 2007-06-28 Impact factor: 3.603
Authors: C L Loprinzi; J C Michalak; S K Quella; J R O'Fallon; A K Hatfield; R A Nelimark; A M Dose; T Fischer; C Johnson; N E Klatt Journal: N Engl J Med Date: 1994-08-11 Impact factor: 91.245
Authors: Debra L Barton; Charles L Loprinzi; Pamela Atherton; Jane Raymond; Tait Shanafelt; Stephanie Hines; Fran Palmieri; Teresa Rummans; Alex A Adjei; Jeff Sloan Journal: Support Cancer Ther Date: 2007-09-01
Authors: Claire Johns; Susan M Seav; Sally A Dominick; Jessica R Gorman; Hongying Li; Loki Natarajan; Jun James Mao; H Irene Su Journal: Breast Cancer Res Treat Date: 2016-03-26 Impact factor: 4.872
Authors: Debra L Barton; Beth I LaVasseur; Jeff A Sloan; Allen N Stawis; Kathleen A Flynn; Missy Dyar; David B Johnson; Pamela J Atherton; Brent Diekmann; Charles L Loprinzi Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: William I Fisher; Aimee K Johnson; Gary R Elkins; Julie L Otte; Debra S Burns; Menggang Yu; Janet S Carpenter Journal: CA Cancer J Clin Date: 2013-01-25 Impact factor: 508.702
Authors: Kunal C Kadakia; Charles L Loprinzi; Pamela J Atherton; Kelliann C Fee-Schroeder; Amit Sood; Debra L Barton Journal: Support Care Cancer Date: 2015-08-08 Impact factor: 3.603
Authors: Vera Atema; Marieke van Leeuwen; Hester S A Oldenburg; Valesca Retèl; Marc van Beurden; Myra S Hunter; Neil K Aaronson Journal: BMC Cancer Date: 2016-11-25 Impact factor: 4.430